Biologics market research report

  • 432 views
Uploaded on

Report on Biologics gives a market insight into products types including Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other, for both human and animal consumption. Market …

Report on Biologics gives a market insight into products types including Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other, for both human and animal consumption. Market projections and estimates are illustrated by region and by type. The report serves as a guide to Biologics industry, covering more than 500 companies that are engaged in Biologics products and services. Major Contract Research Organizations, Research Institutes and Universities serving the Animal Biologics industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to Biologic products is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, and Rest of World with 116 exclusive graphically represented exhibits.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
432
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 1 BIOLOGICS MARKET SIZE Scope of the Study This report on Biologics gives a market insight into product types including Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other, for both human and animal consumption. Market projections and estimates are illustrated by region and by type. The report serves as a guide to Biologics market, covering more than 250 companies that are engaged in Biologics products and services. Major Contract Research Organizations, Research Institutes and Universities serving the Animal Biologics industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to Biologic products is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, and Rest of World with 116 exclusive graphically represented exhibits. Biologics’ report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in--  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets Analytics and data presented in this report pertain to several parameters such as –  Global and Regional Market Sizes, Market Shares, Market Trends  Product (Global and Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies by Sales, Brands, Products  Consumer Behavioral Patterns  Other Strategic Business Affecting Data
  • 2. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 2 Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.
  • 3. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 3 CHAPTER II - REPORT SYNOPSIS Biologics Biologics is a preparation like a drug, a vaccine or an antitoxin which is produced from living organisms or products obtained from them. These are used as diagnostic, preventive or an agent for treatment. The official definition of biologics or biological products according to FDA is “any virus, toxin, antitoxin, therapeutic serum or analogous product that can be used to prevent, treat or cure diseases or injuries of man”. Biopharmaceuticals: This is a pharmaceutical that has been obtained from biological sources particularly those manufactured by using biotechnology. Biosimilars: Biosimilars are also called as follow -on biologics. These are biologic medical products wherein the active drug substance is synthesized by a living organism or derived from a living organism by using either recombinant DNA or controlled gene expression procedure. Monoclonal Antibodies: Monoclonal Antibodies (mAb or moAb) are essentially monospecific antibodies. These are the same as they are made by exactly same immune cells that are clones of a unique parent cell. As opposed to this, polyclonal antibodies are made from several different immune cells. Monoclonal antibodies have monovalent affinity as these bind to the same epitope. Segmentation of Biologics Market Exhibit 1. Segmentation of Global Biologics Market by Type and Species Type Species Monoclonal Antibodies Human Blood & Blood Products Animal Vaccines Insulin Other * Growth Hormones/Factors © RIT, 2013
  • 4. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 4 Global Market Analysis Global Biologics market is projected to reach about US$ XX.XX billion by 2020 from an estimated US$ XX.XX billion in 2012, growing at a very high compounded annual growth rate (CAGR) of XX.XX % during the analysis period 2005-2020. Exhibit 2. Biologics – Global Value Market Estimations and Predictions (2005-2020) in US$ Million Year Value 2005 XX.XX 2006 XX.XX 2007 XX.XX 2008 XX.XX 2009 XX.XX 2010 XX.XX 2011 XX.XX 2012 XX.XX 2013 XX.XX 2014 XX.XX 2015 XX.XX 2016 XX.XX 2017 XX.XX 2018 XX.XX 2019 XX.XX 2020 XX.XX CAGR % XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Million
  • 5. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 5 Exhibit 3. List of Major Global Biologics Companies S. No Company Country Website 1 Abbott Laboratories USA www.abbott.com 2 Novartis Animal Health Switzerland www.ah.novartis.com 3 Sanofi SA France www.sanofi.com 4 Zoetis Animal Health USA www.zoetis.com More… © RIT, 2013
  • 6. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 6 III. MARKET DYNAMICS North American Biologics Market United States is estimated as the largest market for Biologics in North America, with an estimated share of XX.XX % in 2012. In terms of value, United States is projected to reach US$ XX.XX billion by 2020, from an estimated US$ XX.XX billion in 2012. Canada is projected to represent the fastest growing market for Biologics in North American region during 2005-2020 with a CAGR of XX.XX %. Exhibit 4. Biologics - North American Value Market Estimations and Predictions (2005-2020) by Countries for United States and Canada in US$ Billion Year/Country United States Canada Total 2005 XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion United States Canada
  • 7. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 7 Exhibit 5. Biologics - North American Value Market Shares (2010, 2015 & 2020) by Country for United States and Canada Year/Country United States Canada Total 2010 XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX © RIT Figures, 2013 US Biologics Market United States Biologics market is projected to grow at a CAGR of XX.XX % during 2005-2020, to almost reach US$ XX.XX billion by 2020, from an estimated market value of US$ XX.XX billion in 2012. Canadian Biologics Market Canadian Biologics market is projected to grow at a CAGR of XX.XX % during 2005-2020 to reach US$ XX.XX billion by 2020, from an estimated market value of US$ XX.XX billion in 2012.
  • 8. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 8 Biologics - Analysis by Type Global market for Blood & Blood Products is estimated as the largest Biologics segment, valued at US$ XX.XX billion in 2012, accounting for more than half of the market. Blood & Blood Products market is expected to reach about US$ XX.XX billion by 2020, and fastest CAGR of XX.XX %, followed by Monoclonal Antibodies with a CAGR of XX.XX % during the above analysis period 2005-2020. Exhibit 6. Biologics – Global Value Market Estimations and Predictions (2005-2020) by Type for Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other in US$ Billion Year/Region Monoclonal Antibodies Blood & Blood Products Vaccines Insulin Other Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion MonoclonalAntibodies Blood & Blood Products Vaccines Insulin Other
  • 9. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 9 Exhibit 7. Biologics– Global Value Market Shares (2010, 2015 &2020) by Type for Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other Year/Region Monoclonal Antibodies Blood & Blood Products Vaccines Insulin Other Total 2010 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013
  • 10. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 10 IV. PRODUCT/TECHNOLOGY RESEARCH Biologics – Introduction There have been a lot of developments in biotechnology and medicines and this has led to entry and increase of biologics. Chemical drugs are simple, small molecule compounds. These have been developed by chemists and produced in the form of pills. Examples include aspirin, Ibuprofen etc. Biologics are large, complex molecules developed by bioengineered bacteria and other living organisms. These have a great potential for the therapy of cancer, autoimmune diseases and other critical diseases. Drug producers have been promised patent protection and are tempted by the strong market rates so they have ventured into this area. They are working to develop new biologics to be used in several therapeutic areas. Biologics development has not reached its full potential as it is expensive and the second important factor is the safety issue. Therapy with biologics is costly and the total costs may go up to hundreds of thousands of dollars annually. The second important concern is safety. This is due to the fact that biologics are larger and more complex than small-molecule drugs. Hence, the manufacture, quality control and quality assurance is a big problem. Minute changes in a biologic’s production can alter its chemical properties and the way it affects individuals. Competition from generic versions of brand name biologics termed as “follow-on biologics”, would take care of the expenses by providing inexpensive alternatives and also offer growth for generic biologic producers to continue research and development. As such there is no legislative framework to look after approval of generic biologics. As per the Public Health Safety Act (“PHSA”) generic biologics too have to be approved similar to the reference biologics. A biologic medicine is a big molecule which is obtained from living cells and used for therapy, diagnosis or prevention of disease. The biologic medicines are therapeutic proteins, DNA vaccines, monoclonal antibodies and fusion proteins. Biologic medicines are about 200 to 1000 times larger than small molecule drugs and are structurally complex as well. These are very sensitive, so it is difficult to manufacture and categorize these. Due to the properties of size and sensitivity, the biologic medicines are mostly injected into the body of the patient. Exhibit 8. List of Best Selling Biologics Biologic Company Description Patent Expiry Sales (2011) Enbrel Amgen TNF inhibitor 2028 US$ 7.4 billion Novolog Novo Nordisk Insulin Analog 2014 US$ 2.4 billion Lantus Sanofi SA Insulin Analog 2015 US$ 5.4 billion Neulasta Amgen G-CSF 2015 US$ 5.2 billion Humira Abbott ---- ----- ---- Rituxan Genentech ---- ----- ---- More…. © RIT, 2013
  • 11. RITMIR039: Biologics – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 11 About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development. Research – As Good as the Methodology is!  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets © COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company. DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.